JP2018512175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512175A5 JP2018512175A5 JP2018502608A JP2018502608A JP2018512175A5 JP 2018512175 A5 JP2018512175 A5 JP 2018512175A5 JP 2018502608 A JP2018502608 A JP 2018502608A JP 2018502608 A JP2018502608 A JP 2018502608A JP 2018512175 A5 JP2018512175 A5 JP 2018512175A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- glycosylated
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 89
- 230000027455 binding Effects 0.000 claims description 55
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 50
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 239000007850 fluorescent dye Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 102000048776 human CD274 Human genes 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 206010044285 tracheal cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000012216 imaging agent Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 19
- 238000006206 glycosylation reaction Methods 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 12
- 230000013595 glycosylation Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000011394 anticancer treatment Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078780A JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140135P | 2015-03-30 | 2015-03-30 | |
| US62/140,135 | 2015-03-30 | ||
| PCT/US2016/024691 WO2016160792A1 (en) | 2015-03-30 | 2016-03-29 | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078780A Division JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512175A JP2018512175A (ja) | 2018-05-17 |
| JP2018512175A5 true JP2018512175A5 (enExample) | 2019-05-09 |
| JP6936784B2 JP6936784B2 (ja) | 2021-09-22 |
Family
ID=57004606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502608A Active JP6936784B2 (ja) | 2015-03-30 | 2016-03-29 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
| JP2021078780A Pending JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078780A Pending JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10836827B2 (enExample) |
| EP (1) | EP3277320A4 (enExample) |
| JP (2) | JP6936784B2 (enExample) |
| KR (1) | KR102610592B1 (enExample) |
| CN (2) | CN107530429B (enExample) |
| WO (1) | WO2016160792A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| JP6936784B2 (ja) | 2015-03-30 | 2021-09-22 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| US10858432B2 (en) | 2015-12-02 | 2020-12-08 | Stcube, Inc. | Antibodies specific to glycosylated PD-1 and methods of use thereof |
| CN109071636A (zh) | 2016-03-29 | 2018-12-21 | 斯特库比股份有限公司 | 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法 |
| US11660352B2 (en) * | 2016-03-29 | 2023-05-30 | Stcube, Inc. | Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
| KR20190031299A (ko) | 2016-07-20 | 2019-03-25 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법 |
| KR102604433B1 (ko) | 2016-08-09 | 2023-11-24 | 키맵 리미티드 | 항-icos 항체 |
| CN106478819B (zh) * | 2016-10-27 | 2018-12-07 | 常州费洛斯药业科技有限公司 | 一种针对pd-l1的单克隆抗体或抗体片段 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN106496327B (zh) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体 |
| WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| WO2018226671A1 (en) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| SG11202006441SA (en) | 2018-01-15 | 2020-08-28 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| US11976128B2 (en) | 2018-03-23 | 2024-05-07 | Board Of Regents, The University Of Texas System | Human PD-L2 antibodies and methods of use therefor |
| AU2019239568B2 (en) | 2018-03-23 | 2025-09-11 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor |
| EP4501355A3 (en) * | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| WO2019195621A1 (en) * | 2018-04-04 | 2019-10-10 | Immutics, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| CN108315430B (zh) * | 2018-04-28 | 2021-07-23 | 上海交通大学医学院附属仁济医院 | Pdl1 snp基因型作为预测乳腺癌新辅助化疗疗效标记物的用途 |
| JP7332194B2 (ja) * | 2018-06-29 | 2023-08-23 | スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド | Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用 |
| CN110702916B (zh) * | 2019-04-15 | 2022-06-21 | 四川大学华西医院 | 一种整合蛋白质组和糖蛋白组的定量分析方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| US20220356248A1 (en) | 2019-10-09 | 2022-11-10 | Stcube & Co | Antibodies specific to glycosylated lag3 and methods of use thereof |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| IT202000031838A1 (it) * | 2020-12-22 | 2022-06-22 | Saverio Alberti | Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| CN117756915B (zh) * | 2023-11-24 | 2025-05-30 | 河南省肿瘤医院 | 一组阻断抗pd-1抗体与细胞表面pd-1分子结合的pd-1分子及其突变体和用途 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) * | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| CA2508660C (en) * | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| CA2572098C (en) | 2004-06-30 | 2015-01-27 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| US20090011136A1 (en) * | 2005-05-06 | 2009-01-08 | Thomas Steven Lancsek | Composite electroless plating |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| CA3120172A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
| WO2011109246A1 (en) | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| AU2012296576B2 (en) | 2011-08-15 | 2017-09-07 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
| MX349096B (es) * | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| CA2926856A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| FI3083686T4 (fi) | 2013-12-17 | 2023-05-09 | Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja | |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JP6936784B2 (ja) | 2015-03-30 | 2021-09-22 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
| ES2895034T3 (es) | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
-
2016
- 2016-03-29 JP JP2018502608A patent/JP6936784B2/ja active Active
- 2016-03-29 CN CN201680026424.2A patent/CN107530429B/zh active Active
- 2016-03-29 KR KR1020177031205A patent/KR102610592B1/ko active Active
- 2016-03-29 CN CN202111409317.7A patent/CN114380909A/zh active Pending
- 2016-03-29 EP EP16773987.9A patent/EP3277320A4/en active Pending
- 2016-03-29 WO PCT/US2016/024691 patent/WO2016160792A1/en not_active Ceased
- 2016-03-29 US US15/559,513 patent/US10836827B2/en active Active
-
2021
- 2021-05-06 JP JP2021078780A patent/JP2021129572A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512175A5 (enExample) | ||
| US10669339B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| US20160280798A1 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
| CN108368170A (zh) | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 | |
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| TW201643195A (zh) | 對細胞內致癌基因產物的單株抗原結合蛋白 | |
| US9676846B2 (en) | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II | |
| JP2025508118A (ja) | 新規免疫調節剤の開発および使用 | |
| JP6603227B2 (ja) | Ｐ９７融合タンパク質 | |
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| KR20170064545A (ko) | L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171) | |
| US20220056146A1 (en) | Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof | |
| CN106164094A (zh) | 双特异性抗原结合多肽 | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| CA3229327A1 (en) | Antibodies and antigen binding fragments against cd155 methods of use thereof | |
| CN121079324A (zh) | 抗cntn4抗体及其用途 | |
| JP2022504472A (ja) | Ｈｅｒ２結合四量体ポリペプチド | |
| CN120435306A (zh) | 嵌合抗原受体t细胞的可逆控制 | |
| WO2023221935A1 (zh) | 结合pd-l1和cldn18.2的抗体及其用途 | |
| CN118108842A (zh) | 人源化抗cd24抗体及其应用 | |
| JP7080896B2 (ja) | 抗ｄｒ５抗体およびその用途 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| US20220002435A1 (en) | Antibodies targeting epn1 |